Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Albertini

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Human Gene Therapy|May 1, 1997
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcomaD M Mahvi, P M Sondel, N S Yang, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanomaM R Albertini, J Gan, P Jaeger, et al.
Blood|June 1, 1994
Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patientK R Oettel, O H Wesly, M R Albertini, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|January 1, 1992
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cellsM R Albertini, D F Gibson, S P Robinson, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Human Gene Therapy|May 1, 1997
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcomaD M Mahvi, P M Sondel, N S Yang, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanomaM R Albertini, J Gan, P Jaeger, et al.
Blood|June 1, 1994
Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patientK R Oettel, O H Wesly, M R Albertini, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|January 1, 1992
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cellsM R Albertini, D F Gibson, S P Robinson, et al.
Pageof 3